TY - JOUR
T1 - Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism
T2 - Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry
AU - Golemi, Iva
AU - Cote, Lauren
AU - Iftikhar, Omer
AU - Brenner, Benjamin
AU - Tafur, Alfonso
AU - Bikdeli, Behnood
AU - Fernández-Capitán, Carmen
AU - Pedrajas, José María
AU - Otero, Remedios
AU - Quintavalla, Roberto
AU - Monreal, Manuel
AU - Registro Informatizado de Enfermedad Tromboembólica Investigators
A2 - Prandoni, Paolo
A2 - Farge-Bancel, Dominique
A2 - Barba, Raquel
A2 - Di Micco, Pierpaolo
A2 - Bertoletti, Laurent
A2 - Tzoran, Inna
A2 - Reis, Abilio
A2 - Bounameaux, Henri
A2 - Malý, Radovan
A2 - Verhamme, Peter
A2 - Bosevski, Marijan
A2 - Caprini, Joseph A.
A2 - Bui, Hanh My
A2 - Adarraga, M. D.
A2 - Aibar, M. A.
A2 - Aibar, J.
A2 - Amado, C.
A2 - Arcelus, J. I.
A2 - Azcarate, P. M.
A2 - Ballaz, A.
A2 - Barba, R.
A2 - Barrón, M.
A2 - Barrón-Andrés, B.
A2 - Bascuñana, J.
A2 - Blanco-Molina, A.
A2 - Camon, A. M.
A2 - Carrasco, C.
A2 - Castro, J.
A2 - de Ancos, C.
A2 - del Toro, J.
A2 - Demelo, P.
A2 - Díaz-Pedroche, M. C.
A2 - Díaz-Peromingo, J. A.
A2 - Díaz-Simón, R.
A2 - Encabo, M.
A2 - Falgá, C.
A2 - Farfan, A. I.
A2 - Skride, A.
A2 - Sablinskis, K.
A2 - Sablinskis, M.
N1 - Funding Information:
We express our gratitude to Sanofi Spain for supporting the RIETE Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting the RIETE Registry. Bayer Pharma AG's support was limited to the part of RIETE outside of Spain, which accounts for 25.10% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data and logistic and administrative support.
Funding Information:
Conception and design: IG, AT, MM Analysis and interpretation: IG, AT, MM Data collection: IG, LC, OI, BenB, AT, BehB, CF, JP, RO, RQ, MM Writing the article: IG, AT, MM Critical revision of the article: IG, LC, OI, BenB, AT, BehB, CF, JP, RO, RQ, MM Final approval of the article: IG, LC, OI, BenB, AT, BehB, CF, JP, RO, RQ, MM Statistical analysis: Not applicable Obtained funding: Not applicable Overall responsibility: IG IG and AT contributed equally to this article and share co-first authorship. We express our gratitude to Sanofi Spain for supporting the RIETE Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting the RIETE Registry. Bayer Pharma AG's support was limited to the part of RIETE outside of Spain, which accounts for 25.10% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data and logistic and administrative support. Appendix (online only) Coordinator of the RIETE Registry: Dr Manuel Monreal (Spain); RIETE Steering Committee Members: Dr Paolo Prandoni (Italy), Dr Benjamin Brenner (Israel), and Dr Dominique Farge-Bancel (France); RIETE National Coordinators: Dr Raquel Barba (Spain), Dr Pierpaolo Di Micco (Italy), Dr Laurent Bertoletti (France), Dr Inna Tzoran (Israel), Dr Abilio Reis (Portugal), Dr Henri Bounameaux (Switzerland), Dr Radovan Malý (Czech Republic), Dr Peter Verhamme (Belgium), Dr Marijan Bosevski (Republic of Macedonia), Dr Joseph A. Caprini (United States), Dr Hanh My Bui (Vietnam); RIETE Registry Coordinating Center: S&H Medical Science Service; Members of the RIETE Group: Spain—Adarraga MD, Aibar MA, Aibar J, Amado C, Arcelus JI, Azcarate PM, Ballaz A, Barba R, Barrón M, Barrón-Andrés B, Bascuñana J, Blanco-Molina A, Camon AM, Carrasco C, Castro J, de Ancos C, del Toro J, Demelo P, Díaz-Pedroche MC, Díaz-Peromingo JA, Díaz-Simón R, Encabo M, Falgá C, Farfán AI, Fernández-Capitán C, Fernández-Criado MC, Fidalgo MA, Font C, Font L, García MA, García-Bragado F, García-Morillo M, García-Raso A, Gavín O, Gaya I, Gayol MC, Gil-Díaz A, Guirado L, Gómez V, González-Martínez J, Grau E, Gutiérrez J, Hernández Blasco LM, Iglesias M, Jara-Palomares L, Jaras MJ, Jiménez D, Jou I, Joya MD, Lalueza A, Lima J, Llamas P, Lobo JL, López-Jiménez L, López-Miguel P, López-Nuñez JJ, López-Reyes R, López-Sáez JB, Lorente MA, Lorenzo A, Loring M, Lumbierres M, Madridano O, Maestre A, Marchena PJ, Martín-Guerra JM, Martín Fernández M, Mellado M, Monreal M, Morales MV, Nieto JA, Núñez MJ, Olivares MC, Otalora S, Otero R, Pedrajas JM, Pellejero G, Pérez-Pinar M, Pérez-Rus G, Peris ML, Pesce ML, Porras JA, Rivas A, Rodríguez-Dávila MA, Rodríguez-Fernández L, Rodríguez-Hernández A, Rodríguez-Martín C, Rubio CM, Ruiz-Alcaraz S, Ruiz-Artacho P, Ruiz-Ruiz J, Ruiz-Sada P, Sahuquillo JC, Salazar V, Sampériz A, Sánchez-Muñoz-Torrero JF, Sancho T, Sanoja I, Soler S, Soto MJ, Suriñach JM, Tolosa C, Torres MI, Trujillo-Santos J, Uresandi F, Usandizaga E, Valle R, and Vidal G; Argentina—Gutiérrez P, Vázquez FJ, and Vilaseca A; Belgium—Vanassche T, Vandenbriele C, and Verhamme P; Czech Republic—Hirmerova J and Malý R; Ecuador—Salgado E; France—Benzidia I, Bertoletti L, Bura-Riviere A, Debourdeau P, Falvo N, Farge-Bancel D, Hij A, Mahé I, and Moustafa F; Israel: Braester A, Brenner B, Ellis M, and Tzoran I; Italy—Barillari G, Bilora F, Bortoluzzi C, Brandolin B, Bucherini E, Ciammaichella M, Dentali F, Di Micco P, Grandone E, Imbalzano E, Lessiani G, Maida R, Mastroiacovo D, Mumoli N, Vo Hong N, Pace F, Parisi R, Pesavento R, Pinelli M, Prandoni P, Quintavalla R, Rocci A, Siniscalchi C, Tufano A, and Visonà A; Latvia—Skride A, Sablinskis K, and Sablinskis M; Republic of Macedonia—Bosevski M and Zdraveska M; Switzerland—Bounameaux H, Fresa M, Ney B, and Mazzolai L; United States—Caprini J, and Tafur A; Vietnam—Bui HM. Appendix Additional material for this article may be found online at www.jvsvenous.org .
Publisher Copyright:
© 2019 Society for Vascular Surgery
PY - 2020/5
Y1 - 2020/5
N2 - Objective: Overlap exists between the risk factors for coronary artery disease and venous thromboembolism (VTE). However, a paucity of data is available on the incidence of major acute cardiovascular events (MACE) and major adverse limb events (MALE) among patients presenting with VTE. Moreover, it is unknown whether the rate of cardiovascular outcomes differs among patients with unprovoked vs provoked VTE. Methods: We analyzed the data from 2009 to 2017 in the Registro Informatizado de Enfermedad Tromboembólica registry, an ongoing, multicenter, international registry of consecutive patients with a diagnosis of objectively confirmed VTE. The query was restricted it to patients with data entry for the arterial outcomes. The baseline prevalence of coronary artery disease risk factors was compared between patients with provoked (ie, immobility, cancer, surgery, travel >6 hours, hormonal causes) and unprovoked VTE. After the initial VTE event, we followed up patients for the composite primary outcome of incident MACE (ie, stroke, myocardial infarction, unstable angina) and/or MALE (ie, major limb events). We used the χ2 test for baseline associations and a Cox proportional hazard for multivariate analysis. We used IBM SPSS, version 24 (IBM Corp, Armonk, NY) for statistical analysis. A P value of <.05 was considered statistically significant. Results: We analyzed the data from 41,259 patients with VTE, of whom 22,633 (55.6%) had experienced a provoked VTE. During follow-up, the patients with provoked VTE were more likely to develop MACE or MALE than were patients with unprovoked VTE (hazard ratio [HR], 1.3; 95% confidence interval [CI], 1.1-1.5). The association of arterial events with recent immobility (HR, 1.4; 95% CI, 1.5-12.1) and cancer (HR, 1.7; 95% CI, 1.4-1.9) was strong. After adjusting for multiple conventional cardiovascular risk factors, provoked VTE, compared with unprovoked VTE, was significantly associated with an increased hazard for MACE (HR, 1.4; 95% CI, 1.1-1.7). Cancer remained a significant adjusted predictor for both MACE (HR, 1.7; 95% CI, 1.4-2.1) and MALE (HR, 2.1; 95% CI 1.01-4.6) in those with provoked VTE. Conclusions: Among patients with VTE, provoked cases, specifically those with cancer-associated VTE, have an increased risk of major arterial events.
AB - Objective: Overlap exists between the risk factors for coronary artery disease and venous thromboembolism (VTE). However, a paucity of data is available on the incidence of major acute cardiovascular events (MACE) and major adverse limb events (MALE) among patients presenting with VTE. Moreover, it is unknown whether the rate of cardiovascular outcomes differs among patients with unprovoked vs provoked VTE. Methods: We analyzed the data from 2009 to 2017 in the Registro Informatizado de Enfermedad Tromboembólica registry, an ongoing, multicenter, international registry of consecutive patients with a diagnosis of objectively confirmed VTE. The query was restricted it to patients with data entry for the arterial outcomes. The baseline prevalence of coronary artery disease risk factors was compared between patients with provoked (ie, immobility, cancer, surgery, travel >6 hours, hormonal causes) and unprovoked VTE. After the initial VTE event, we followed up patients for the composite primary outcome of incident MACE (ie, stroke, myocardial infarction, unstable angina) and/or MALE (ie, major limb events). We used the χ2 test for baseline associations and a Cox proportional hazard for multivariate analysis. We used IBM SPSS, version 24 (IBM Corp, Armonk, NY) for statistical analysis. A P value of <.05 was considered statistically significant. Results: We analyzed the data from 41,259 patients with VTE, of whom 22,633 (55.6%) had experienced a provoked VTE. During follow-up, the patients with provoked VTE were more likely to develop MACE or MALE than were patients with unprovoked VTE (hazard ratio [HR], 1.3; 95% confidence interval [CI], 1.1-1.5). The association of arterial events with recent immobility (HR, 1.4; 95% CI, 1.5-12.1) and cancer (HR, 1.7; 95% CI, 1.4-1.9) was strong. After adjusting for multiple conventional cardiovascular risk factors, provoked VTE, compared with unprovoked VTE, was significantly associated with an increased hazard for MACE (HR, 1.4; 95% CI, 1.1-1.7). Cancer remained a significant adjusted predictor for both MACE (HR, 1.7; 95% CI, 1.4-2.1) and MALE (HR, 2.1; 95% CI 1.01-4.6) in those with provoked VTE. Conclusions: Among patients with VTE, provoked cases, specifically those with cancer-associated VTE, have an increased risk of major arterial events.
KW - Major adverse cardiovascular events
KW - Major adverse limb events
KW - Provoked
KW - Venous thromboembolism
KW - VTE
UR - http://www.scopus.com/inward/record.url?scp=85076527435&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/31784355/
U2 - 10.1016/j.jvsv.2019.03.011
DO - 10.1016/j.jvsv.2019.03.011
M3 - Article
C2 - 31784355
AN - SCOPUS:85076527435
SN - 2213-333X
VL - 8
SP - 353-359.e1
JO - Journal of Vascular Surgery: Venous and Lymphatic Disorders
JF - Journal of Vascular Surgery: Venous and Lymphatic Disorders
IS - 3
ER -